Expert-led podcast: Exploring sALCL case studies and the treatment landscape
Prescribing information is available at the top of the page.
Listen to Dr Matthew Wilson, Consultant Haematologist at the Beatson West of Scotland Cancer Centre, and Dr Wendy Osborne, Consultant Haematologist at Newcastle Hospitals NHS Foundation Trust, discuss diverse clinical presentations of sALCL and their personal management strategies by exploring two real-world patient case studies.
Dr Wilson and Dr Osborne also discuss the use of ADCETRIS®(brentuximab vedotin) as a treatment option for adult patients with sALCL, including in first-line in combination with CHP based on evidence from the ECHELON-2 study1 and also as monotherapy in adult patients with R/R sALCL.
CHP, cyclophosphamide, doxorubicin and prednisone; R/R, relapsed or refractory; sALCL, systemic anaplastic large cell lymphoma. 1. Horwitz S et al. Lancet 2019;393:229–40.
To enjoy the full experience of OncoConnect, including the ability to like and bookmark content for easy access via your account section, please register or login now.
